Citadel Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $126M | Sell |
637,000
-118,450
| -16% | -$22.8M | 0.02% | 670 |
|
|
2025
Q4 | $139M | Buy |
755,450
+49,950
| +7% | +$8.76M | 0.02% | 669 |
|
|
2025
Q3 | $108M | Sell |
705,500
-431,950
| -38% | -$65.4M | 0.02% | 784 |
|
|
2025
Q2 | $159M | Buy |
1,137,450
+294,700
| +35% | +$41.3M | 0.03% | 504 |
|
|
2025
Q1 | $124M | Sell |
842,750
-503,550
| -37% | -$72.9M | 0.02% | 574 |
|
|
2024
Q4 | $176M | Buy |
1,346,300
+699,150
| +108% | +$97.9M | 0.03% | 454 |
|
|
2024
Q3 | $101M | Sell |
647,150
-461,050
| -42% | -$74.4M | 0.02% | 692 |
|
|
2024
Q2 | $173M | Buy |
1,108,200
+230,900
| +26% | +$34.7M | 0.04% | 406 |
|
|
2024
Q1 | $119M | Buy |
877,300
+281,550
| +47% | +$37.3M | 0.02% | 605 |
|
|
2023
Q4 | $80.2M | Sell |
595,750
-263,700
| -31% | -$34.3M | 0.02% | 824 |
|
|
2023
Q3 | $116M | Buy |
859,450
+483,500
| +129% | +$66M | 0.03% | 548 |
|
|
2023
Q2 | $53.8M | Buy |
375,950
+105,000
| +39% | +$15.4M | 0.01% | 991 |
|
|
2023
Q1 | $37.6M | Sell |
270,950
-105,216
| -28% | -$14.2M | 0.01% | 1325 |
|
|
2022
Q4 | $51M | Buy |
376,166
+175,868
| +88% | +$22.1M | 0.01% | 1106 |
|
|
2022
Q3 | $22M | Sell |
200,298
-56,356
| -22% | -$7.15M | 0.01% | 1779 |
|
|
2022
Q2 | $33.9M | Sell |
256,654
-138,300
| -35% | -$18.1M | 0.01% | 1361 |
|
|
2022
Q1 | $52.4M | Sell |
394,954
-123,910
| -24% | -$14.9M | 0.01% | 1087 |
|
|
2021
Q4 | $60.4M | Sell |
518,864
-183,862
| -26% | -$21.6M | 0.01% | 1029 |
|
|
2021
Q3 | $84.4M | Buy |
702,726
+433,226
| +161% | +$50.4M | 0.02% | 750 |
|
|
2021
Q2 | $32.3M | Sell |
269,500
-25,800
| -9% | -$2.83M | 0.01% | 1536 |
|
|
2021
Q1 | $29.4M | Buy |
295,300
+161,450
| +121% | +$16.2M | 0.01% | 1540 |
|
|
2020
Q4 | $13.4M | Sell |
133,850
-148,500
| -53% | -$15.7M | ﹤0.01% | 2260 |
|
|
2020
Q3 | $30.9M | Sell |
282,350
-135,350
| -32% | -$15.1M | 0.01% | 1192 |
|
|
2020
Q2 | $44.2M | Buy |
417,700
+283,450
| +211% | +$29.3M | 0.02% | 883 |
|
|
2020
Q1 | $12M | Buy |
134,250
+66,450
| +98% | +$6.26M | 0.01% | 1680 |
|
|
2019
Q4 | $6.76M | Buy |
67,800
+5,350
| +9% | +$504K | ﹤0.01% | 2696 |
|
|
2019
Q3 | $5.57M | Sell |
62,450
-13,500
| -18% | -$1.17M | ﹤0.01% | 2962 |
|
|
2019
Q2 | $6.27M | Sell |
75,950
-7,850
| -9% | -$616K | ﹤0.01% | 2768 |
|
|
2019
Q1 | $6.78M | Sell |
83,800
-48,750
| -37% | -$3.84M | ﹤0.01% | 2568 |
|
|
2018
Q4 | $10.1M | Sell |
132,550
-1,100
| -0.8% | -$85.9K | 0.01% | 1882 |
|
|
2018
Q3 | $10.6M | Buy |
133,650
+7,800
| +6% | +$590K | ﹤0.01% | 2034 |
|
|
2018
Q2 | $8.84M | Sell |
125,850
-61,350
| -33% | -$4.41M | ﹤0.01% | 2072 |
|
|
2018
Q1 | $13.1M | Buy |
187,200
+61,150
| +49% | +$4.24M | 0.01% | 1489 |
|
|
2017
Q4 | $8.75M | Sell |
126,050
-124,900
| -50% | -$8.42M | 0.01% | 1863 |
|
|
2017
Q3 | $17M | Buy |
250,950
+13,000
| +5% | +$821K | 0.01% | 1192 |
|
|
2017
Q2 | $16.2M | Buy |
237,950
+117,250
| +97% | +$7.66M | 0.01% | 1116 |
|
|
2017
Q1 | $7.52M | Buy |
120,700
+39,500
| +49% | +$2.3M | 0.01% | 1652 |
|
|
2016
Q4 | $4.44M | Sell |
81,200
-15,800
| -16% | -$897K | ﹤0.01% | 2124 |
|
|
2016
Q3 | $6.38M | Sell |
97,000
-24,100
| -20% | -$1.58M | 0.01% | 1739 |
|
|
2016
Q2 | $7.31M | Buy |
+121,100
| New | +$7.03M | 0.01% | 1493 |
|
Other funds holding AZN
IA
VCM
VAM
Citadel Advisors's AZN Position: Q1 2026 in Review
Citadel Advisors increased its AstraZeneca (AZN) stake by 345% in Q1 2026, buying an estimated $280M and bringing the position to 1,869,793 shares worth $369M. The position accounts for 0.06% of the portfolio, ranked #251.
Citadel Advisors first reported a position in AZN in Q2 2013 and has held it in 50 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Citadel Advisors held 1,869,793 shares of AstraZeneca worth $369M as of Q1 2026.
- Citadel Advisors bought 1,449,726 AstraZeneca shares in Q1 2026, an estimated $280M.
- AstraZeneca made up 0.06% of Citadel Advisors's portfolio in Q1 2026, its #251 holding.
- Citadel Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 50 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.